HTA publishes licence fee levels for the 2026 to 2027 business year

Following the HTA Board’s approval, the Human Tissue Authority has confirmed the new regulatory fee structure for the 2026/27 financial year. This adjustment, which represents a modest increase above the current rate of inflation, is essential to ensure the continued delivery of high-quality regulatory oversight.

The revised fees address two primary organisational requirements. They account for inflationary pressures on core operational costs—including staff salaries, accommodation, travel, and IT support—while also funding the HTA’s ongoing Digital and IT Strategy. This investment focuses on modernising systems and digitising services to ensure interactions with licensed establishments are simpler and more efficient.

The HTA is now conducting targeted stakeholder engagement ahead of the formal publication of the new fee schedule. All licensed establishments will be given formal notice of the finalised fees well in advance of the new financial year, which commences in April 2026.